| Literature DB >> 35919717 |
Chuan Wan1, Yuena Wang1, Chenshan Lian2, Qi Chang2, Yuhao An2, Jiean Chen2, Jinming Sun1, Zhanfeng Hou2, Dongyan Yang3, Xiaochun Guo1, Feng Yin2, Rui Wang2, Zigang Li1,2.
Abstract
Histidine (His, H) undergoes various post-translational modifications (PTMs) and plays multiple roles in protein interactions and enzyme catalyzed reactions. However, compared with other amino acids such as Lys or Cys, His modification is much less explored. Herein we describe a novel visible-light-driven thioacetal activation reaction which enables facile modification on histidine residues. An efficient addition to histidine imidazole N3 under biocompatible conditions was achieved with an electrophilic thionium intermediate. This method allows chemo-selective modification on peptides and proteins with good conversions and efficient histidine-proteome profiling with cell lysates. 78 histidine containing proteins were for the first time found with significant enrichment, most functioning in metal accumulation in brain related diseases. This facile His modification method greatly expands the chemo-selective toolbox for histidine-targeted protein conjugation and helps to reveal histidine's role in protein functions. This journal is © The Royal Society of Chemistry.Entities:
Year: 2022 PMID: 35919717 PMCID: PMC9297702 DOI: 10.1039/d2sc02353a
Source DB: PubMed Journal: Chem Sci ISSN: 2041-6520 Impact factor: 9.969
Fig. 1Histidine-specific bioconjugation: (a) typical methods for His-specific modification of peptides and proteins; (b) visible-light-promoted His-specific bioconjugation.
Optimization of the photocatalyzed reaction of Boc-His-OMe 2 and thioacetal 1a
|
| ||
|---|---|---|
| Entry | Change from standard conditions | Yield |
| 1 | None | 84 |
| 2 | Dark | Trace |
| 3 | 50 °C in the dark | Trace |
| 4 | Catalyst is absent | <10 |
| 5 | 5% catalyst loading | 68 |
| 6 | [Ir(ppy)2(dtbpy)]PF6 instead of RB | 39 |
| 7 | MesAcrClO4 instead of RB | 66 |
| 8 | 4 h instead of 1 h | 85 |
| 9 | Addition of AcOH (2 equiv.) | 83 |
| 10 | Addition of (NH4)2CO3 (2 equiv.) | 80 |
| 11 | Addition of TEMPO (1 equiv.) | Trace |
Standard conditions: thioacetal 1a (20 mM), Boc-His-OMe 2 (5 mM) and 10 mol% Rose Bengal (RB) in MeCN/H2O (4/1) under irradiation with a blue LED (10 W) at 30 °C under air for 1 hour.
Isolated yield obtained by column chromatography.
Determined by LC-MS. TEMPO = 2,2,6,6-tetramethylpiperidine-1-oxyl.
Fig. 2Visible-light-promoted Pummerer-type reaction between thioacetal and the side chain of His. (a) Reaction between thioacetals 1 and Boc-His-OMe/peptides. Standard conditions: thioacetal (20 mM), Boc-His-OMe 2 (5 mM) or peptide (0.5–1 mM) and 10 mol% RB in MeCN/H2O (4/1, pH 7.4) under irradiation with a blue LED (10 W, 450 nm) at 30 °C under air for 1 h. The % yields of peptide products were determined from reverse-phase HPLC-MS with an internal standard (dibenzyl sulfoxide). aIsolated yield. bThe yields in square parentheses refer to thioacetal-adducted products with Met oxidation. (b) Proposed mechanism.
Fig. 3Selective histidine labeling. (a) Structures of thioacetal probes. (b) Labeling of TA1 and TA2 with CA (CA/TA1 and TA2 10/200 μM, 5% RB, pH 7.4, 37 °C for 2 h under blue light (10 W, 450 nm)) and MCF7 cell lysates (40 μg). (c) Labeling of BSA with the probes TA3–7 (BSA/TA3–7 10/200 μM, pH 7.4, 37 °C for 2 h under blue light). FL = in-gel fluorescence scanning. CBB = Coomassie gel. (d) BSA (10 μM) incubated with TA4 (200 μM) with or without light. (e) BSA (10 μM) incubated with TA4 (200 μM) in phosphate buffer with different pHs. (f) Dose-dependent labeling of BSA (10 μM) with TA4 for 2 h. (g) Time-dependent labeling of BSA (10 μM) with TA4 (200 μM). (h) Competitive labeling of BSA (10 μM) with TA4 (200 μM) in the presence or absence of competitor 1a. (i) Labeling of BSA (10 μM) with TA4 (200 μM) in the presence or absence of IAA. (j) Labeling of BSA (10 μM) with TA4 (200 μM) in the presence or absence of NHS-Ace. (k) Analysis of the amino acid specificity of TA4 with IAA-pretreated BSA. (l) TA8 did better labeling with CA (BSA/TA4 and TA8 10/200 μM, 1% RB, pH 7.4, 37 °C for 2 h under blue light). (m) Dose-dependent labeling of MCF7 cell lysates with TA8. (n) Competitive labeling of MCF7 cell lysates with TA8 in the presence or absence of competitor 1b.
Fig. 4Proteome-wide quantification of reactive and exposed histidine-containing proteomes. (a) General protocol for reactive and exposed histidine-containing proteome profiling by label-free TOP-ABPP. Cellular lysates are labeled with the thioacetal-group probe (TA8) at different concentrations and DMSO control. Labeled samples are conjugated to the photo-cleavable biotin tag (green, red, and blue for DMSO, and 10 and 80 μM TA8 probe treatment groups, respectively) by CuAAC click chemistry and incubated, and TA8 labeled proteins are enriched by neutravidin-conjugated beads and digested with trypsin to yield labeled proteins for LC-MS/MS analysis. (b) Volcano plot of differentially enriched proteins under dose dependent TA8 probe groups (n = 3). (c) Venn diagram of highly enriched proteins in each dose-treatment group. (d) KEGG pathway analysis of highly reactive and exposed proteins in 80 μM TA8 proteome. Fold change ≥ 1.5, false discovery rate (FDR) ≤ 0.01, q-value ≤ 0.05. Proteins with significantly enriched proteome are shown in the ESI.†